Clinical trials are research investigations in which people volunteer to test new treatments, interventions or tests as a means to prevent, detect, treat or manage various diseases or medical conditions.
Vigil is a fully personalized cancer immunotherapy utilizing genetically modified tumor cells. To date, we have conducted Phase 1 studies identifying the clinical dose and established the early safety profile for the platform.
The tumor types studied in Phase 1 included, but not limited to: Ovarian cancer, breast cancer, melanoma, Ewing’s sarcoma, non-small cell lung cancer, colon cancer, and hepatocellular cancer. We have also initiated Phase 2 studies in advanced ovarian cancer and Ewing’s sarcoma.
We are currently conducting clinical studies with primary focus on Vigil immunotherapy in patients with recurrent / refractory Ewing’s sarcoma, as well as in combination with other immunotherapies, such as checkpoint inhibitors in patients with advanced women’s cancers.
